New projects to fast-track progress with Innobooster

Organised by the Gebert Rüf Stiftung, the Innobooster program supports entrepreneurs with innovative, science-based deep tech project in the Venture Kick process and promise high market potential. Each selected venture receives CHF 150,000 to fast-track their time to market.

The newly selected projects are:

Tune Insight: Secure Collective ML-as-a-Service
Data plays an increasingly important role in how organisations make decisions. However, most data-driven organisations realise that their data is insufficient; they need access to more complete information to build an accurate worldview and make sound data-backed decisions. Unfortunately, setting up collaborations around sensitive or confidential data is cumbersome, and organisations are reluctant to collaborate with others because of risks of data leaks, data privacy concerns and regulations. Tune Insight enables organisations to collaborate securely to extract collective analytics from their encrypted confidential and sensitive data while remaining in complete control of their data. This project focuses on the improvement and operationalisation of more complex secure machine learning tools that can respond to the needs of modern data-driven organisations, increasing the accessibility and impact of our platform in multiple verticals.

FimmCyte: Novel antibody-based endometriosis treatments
Approximately 20% of the 176 million women affected by endometriosis undergo hysterectomies per year in the G7+China, each costing between $10-20K in direct and indirect costs. Current endometriosis treatments are unspecific, incompatible with fertility, and ineffective in 1 in 3 women. The situation is dreadful for women with late stages of endometriosis for whom there is another intervention other than invasive surgeries – the complete removal of the uterus. There is an unmet medical need for targeted treatments for endometriosis that apply to these advanced stages and can spare the women the pain and uterus.
FimmCyte is developing a novel immune system-based treatment, which demonstrated positive results through early preclinical studies. The startup team, led by Mohaned Shilaih, believes the treatment will apply to most patients. Even at 20% applicability, there would be 800 million to 1.6 billion in savings for the healthcare systems and incalculable physical and psychological value for the affected women.

MYLEG: sensory feedback in prothesis
Lower-limb amputees use prostheses that do not restore sensory feedback, resulting in falls, loss of confidence in the prosthesis, increased fatigue and reduced mobility. Developed by Giacomo Valle, MYLEG aims to improve mobility and prosthesis integration by restoring sensory feedback in leg amputees during their daily lives. Their Product, MYLEG is a unique device acting as an add-on to commercially-available prostheses to restore sensory feedback to amputees by stimulating with pulses of current the skin of their stump. Using this noval product will save the National Health Systems up to €330k per amputee connected to a sedentary lifestyle. The medical device will be sold to rehabilitation clinics, prosthesis manufacturers and directly to patients. The prosthesis market is worth €1.2billion, yet are no similar devices available for patients. MYLEG has a 3-years roadmap to take an effective technology to the market.

The next submission deadline for the Innobooster program expires on 01.05.2022.

(RAN)